Monoclonal Antibody

单抗核心设备(MACF)有助于获得和开发新的 癌症中心研究人员用于研究的抗体。在某些情况下，抗体是 以适合体内临床前研究的数量和纯度制备。因此，mscf是一个充满活力的 和创新的核心，为中心的基本和翻译使命做出广泛贡献。特指 核心开发新的单抗/杂交瘤对感兴趣的特定抗原，在所需的工作 申请。该设施通过以下方式提供对单抗的访问：1)生产单抗(在 体外)；2)纯化单抗；3)将单抗与荧光、蛋白质、Q点结合；3)将单抗碎裂成 Fab和/或F(Ab‘)2片段。细胞培养是癌症研究的主要内容，而健康细胞对 从这些体外系统中获取固体和可重现的数据。自从支原体污染 显著改变细胞过程，常规测试是一种很好的实验室做法。最大限度地减少问题 对于此类污染，MACF还提供支原体检测服务。所提供的服务 在过去的一年里，单抗核心支持了78名研究人员的研究。在过去 授权期核心的工作已经为6项研究中的149篇研究人员的出版物做出了贡献 项目，汉斯-吉多·温德尔实验室最近的一篇论文说明了该设施是如何满足 新的要求。温德尔的研究表明，可溶性Eph受体A7抑制肿瘤生长。这 被归类为肿瘤抑制因子的事实进一步支持了它在~70%的卵泡中丢失的事实 淋巴瘤。纯化抗CD20-EPHA7重组融合抗体的MACF 温德尔组对荷瘤小鼠有一定的治疗作用。这个定制的嵌合体 蛋白质在缩小大肿瘤方面比亲本CD20抗体(利妥昔单抗)更有效。

The Monoclonal Antibody Core Facility (MACF) facilitates the acquisition and development of new antibodies for research studies by investigators in the Cancer Center. In some cases, antibodies are prepared in quantities and with purity suitable for in vivo preclinical studies. As such the MSCF is a vibrant and innovative core that contributes broadly to the basic and translational mission of the Center. Specifically the Core develops new MAbs/ hybridomas to a specific antigen of interest that work in the required application. The facility provides access to MAbs not otherwise readily available by: 1) Producing MAbs (in vitro); 2) Purifying MAbs; 3) Conjugating MAbs to fluorphores, proteins, Q dots; 3) Fragmenting MAbs into Fab and/or F(Ab')2 fragments. Cell cultures are a staple in cancer research and healthy cells are essential to acquiring solid and reproducable data from these in vitro systems. Since mycoplasmal contamination significantly alters cellular processes, routine testing is a good laboratory practice. To minimize problems from such contaminations the MACF also offers a mycoplasma testing service. The services provided by the Monoclonal Antibody Core have supported the research of 78 investigators in the past year. During the past grant period the work of the Core has contributed to 149 publications of researchers from 6 research programs, A recent paper from the laboratory Hans-Guido Wendel illustrates how the facility also meets novel requests. Wendel's work demonstrated that soluble Eph-receptor A7 suppresses tumor growth. This classification as a tumor suppressor is further supported by the fact that it Is lost in ~ 70% follicular lymphomas. The MACF contributed by purifying an anti-CD20-EPHA7 recombinant fusion antibody the Wendel group produced which had a therapeutic effect In tumor bearing mice. This customized chimeric protein was more effective than the parental CD20 antibody (Rituximab) at shrinking large tumors.